Sales & Marketing

The combined company is expected to deliver a superior health care experience and drive better outcomes.

Rohit Gupta, vice president of analytics strategy and transformation at Beghou Consulting, addresses the controversial middlemen of the drug pricing world, the pharmacy benefit managers (PBMs). Can increased competition and other innovative solutions loosen their grip and prevent further consolidation?

Indegene's Jitesh Sah, Vice President, Analytics and Vikas Mahajan, Sr. Director, Data & Analytics chat with senior editor Fran Pollaro about the challenge of data drift.

TikTok is facing a potential ban in the US over national security concerns and advertisers are avoiding the platform or putting together contingency plans.

The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.

Pharma firm is seeking buyers for front-of-eye portfolio and assets include Xiidra, which had $487 million of sales in 2022.

Havas Health & You to navigate complexities around value, access, pricing, and reimbursement.

Pfizer will pay pay $229 a share in cash for the cancer specialist.

Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.

Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal worth $1.7 billion, with Myovant being delisted from the New York Stock Exchange and its shares no longer publicly traded.

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

How platforms like ChatGPT could transform engagement models.

Building on Organon’s prior FP2030 commitment, the company announces $30 million in new funding to fuel global action and community-driven solutions needed by the 121 million women and girls who experience unplanned pregnancies each year.

Nelarabine Injection ensures access to a lifesaving treatment, particularly for children, that historically has been in shortage.

Standard Media Index's latest data suggests that 2022 may have been a tipping point in the transition to digital pharma advertising.

Pharmaceutical companies are increasingly using radio advertising, both traditional and digital.

Survey: HCPs Rank Corporate Reputation as Leading Factor After Drug Efficacy and Safety

Enterprise generative AI focused on life sciences to bring life-saving drugs to market faster.

The drug is Xspray Pharma's first innovative cancer therapy and is set to launch later in 2023.

Blueprint Medicines Corporation will regain global commercialization and development rights to Gavreto (pralsetinib).

The therapy to treat a type of inherited bleeding disorder known as hemophilia A is expected to launch in the United States in April.

Wall Street Journal reports psychedelic-therapy industry gets a reality trip as investors focus on treatments costing less time and money

Bausch + Lomb has launched a social media campaign called "What Sight Inspires You" to raise awareness of age-related macular degeneration.

Sermo and LiveWorld survey of 50+ pharma marketers and 200+ physicians finds that social media plays a major role in influencing perceptions of medications, prescribing Habits, ongoing medical education and professional networking.

The capabilities will support life sciences organizations with a variety of use cases, including health care provider (HCP) interactions, HCP education, and patient education.

A new study shows that a growing number of younger generations are turning to social media platforms such as TikTok and Instagram influencers for health advice.

Move enables FINN to address pressing health priorities in developed and developing nations and expands Hyderus global service capabilities and client offerings and Hyderus co-founders Mark Chataway and Christopher Nial join FINN global health leaders team.

Webinar Date/Time: Mon, Mar 13, 2023 11:00 AM EDT

Takeda's partnership with Novavax to manufacture 150 million doses of COVID-19 vaccine has been heavily impacted.

AstraZeneca is forecasting growth in 2023 and beyond, relying on its expanding line of cancer, metabolic, and rare disease drugs to offset declining COVID product sales.